Acino International
| Acino International AG
|
|
|---|---|
 |
|
| legal form | Corporation |
| ISIN | CH0021190902 |
| founding | 1836 |
| Seat | Zurich , Switzerland |
| management | Steffen Saltofte (Chairman of the Management Board ) Håkan Björklund ( Chairman of the Board of Directors ) |
| Number of employees | 1,900 |
| sales | 313 million euros |
| Branch | Pharma |
| Website | www.acino.swiss |
| Status: 2017 | |
The Acino International AG (until the end of January 2016 , Acino Holding AG ), based in Zurich is in the areas of generic and specialty pharmaceuticals internationally active Swiss companies. The group of companies employs around 1,300 people and in 2013 generated sales of almost 300 million euros. The company was at times on the Swiss Exchange SIX Swiss Exchange listed , the shares still in circulation after an acquisition in 2013, but were taken with effect on 17 September 2014 the trade.
Field of activity
Acino specializes in the development, registration and manufacture of generic and patented pharmaceuticals using complex formulation technologies. With a focus on solid oral dosage forms with modified release of active ingredients, therapeutic systems for transdermal drug delivery such as plasters and biodegradable, subcutaneous implants, Acino supplies various suppliers on the European pharmaceutical markets.
In addition to its headquarters in Zurich , the company has locations in Liesberg (Switzerland) and Aesch (Switzerland).
The location in Liesberg focuses on solid dosage forms with delayed release of active ingredients . In addition to the development and manufacture of specialty generics, complementary services such as registration, procurement of active ingredients, packaging and logistics are carried out.
The new production and logistics building is located at the Aesch site. Among other things, it includes around 3000 m² of manufacturing space and a fully automated high-bay warehouse with 8000 pallet spaces.
history
The company was founded in 1836 on the occasion of the discovery of a salt storage facility as the first Swiss saltworks in what is now the Schweizerhalle industrial estate . In the following decade the saltworks was converted into a chemical factory, the "chemical factory on Schweizerhalle", which specialized in the manufacture of chemicals . At the turn of the century, the branches of business were expanded to include the petroleum business and a feed department. Between the two world wars, trade was introduced as a further mainstay alongside the production of chemicals. Schweizerhall sells grain, animal feed, mineral oils, pharmaceutical raw materials and fertilizers, among other things.
With the purchase of Aerosol-Service AG in Möhlin, a company in the perfume sector, another branch of the company was added at the end of the 1970s. This was further expanded in the following years. A 30-year license agreement was signed with Boucheron, Place Vendôme Paris, one of the most exclusive jewelers in the world. A few years later, Schweizerhall was represented in 90 countries with the Boucheron brand. As a result, Schweizerhall took over the traditional Parisian company completely.
The internationalization in the chemical and pharmaceutical sectors was largely achieved through acquisitions. The proceeds from the sale of Boucheron to Gucci in 2000 gave Schweizerhall new room for maneuver and development in order to pursue a dual strategy consisting of the traditional Swiss chemical business on the one hand and investments in the areas of healthcare, biotechnology and life science on the other.
In 2001 the international activities in the pharmaceutical trade were turned against a participation in the Aceto Corp. sold. The assets of the American subsidiary for custom synthesis, Schweizerhall Greenville Inc., were exchanged in 2002 for a stake in IRIX Pharmaceuticals Inc., which is also active in custom synthesis. In the same year, a diversified portfolio of 14 investments in biotechnology companies was acquired by the Geneva-based private bank Lombard Odier Darier Hentsch & Cie. taken from their immunology fund.
In 2004, the company entered the rapidly growing European generics market with the purchase of the generics supplier CIMEX Pharma AG, which specializes in solid dosage forms with controlled release of active ingredients. The repositioning of the Schweizerhall Group in the pharmaceutical market was pushed further in 2006 with the acquisition of Novosis AG, based in Miesbach near Munich. As part of the reorientation towards the pharmaceutical sector, the group of companies sold its former core, Schweizerhall Chemie AG, to Brenntag AG in May 2006.
At the general assembly held on March 28, 2008, the shareholders approved the renaming of Schweizerhall Holding AG and its subsidiaries to Acino. The name change was completed at the end of August 2008.
In February 2012, Acino completed the takeover of the international business activities of the Swiss pharmaceutical company Mepha . The Mepha location in Aesch , which also includes production facilities and research and development, was also taken over.
In October 2013 Pharma Strategy Partners GmbH, a wholly owned subsidiary of Avista Capital Partners and Nordic Capital, submitted a public purchase offer for all publicly held registered shares of Acino Holding AG. After expiry of the grace period on December 5, 2013, the takeover was reported as completed, as over 90% of the shares could be acquired.
In November 2016, Acino announced the sale of its transdermal patch and implant department in Miesbach to Luye Pharma Group Ltd. known.
Web links
- Acino Holding AG website
- Inventory of Chemische Fabrik Schweizerhall AG and Schweizerhall Holding AG in the Swiss Economic Archives
Individual evidence
- ↑ Press release: Acino completes takeover of business activities from Mepha (PDF; 34 kB) on February 17, 2012.
- ↑ Press release: Avista Capital Partners and Nordic Capital hold 93.58% of Acino's share capital (PDF; 65 kB) dated December 6, 2013.
- ↑ Acino closes the deal to divest its patch business to Luye Pharma Group Ltd. | Acino. Retrieved July 20, 2018 .